Interleukin-17-dependent autoimmunity to collagen type v in atherosclerosis

Circulation Research

Volumn 107, Issue 9, 2010, Pages 1106-1116

  Dart, Melanie L ^a   Jankowska Gan, Ewa ^a   Huang, Guorui ^a   Roenneburg, Drew A ^a   Keller, Melissa R ^a   Torrealba, Jose R ^a   Rhoads, Aaron ^b   Kim, Byoungjae ^a   Bobadilla, Joseph L ^a   Haynes, Lynn D ^a   Wilkes, David S ^b   Burlingham, William J ^a   Greenspan, Daniel S ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

atherosclerosis; autoimmunity; collagen type V; interleukin 17

Indexed keywords

APOLIPOPROTEIN E; COLLAGEN TYPE 5; INTERLEUKIN 10; INTERLEUKIN 17;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; AUTOIMMUNITY; BLOOD VESSEL WALL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SENSITIZATION; TH17 CELL;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; AUTOIMMUNE DISEASES; CATTLE; COLLAGEN TYPE V; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-17; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, SCID; TH1 CELLS;

EID: 78349310014     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.110.221069     Document Type: Article

References (52)

1. Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in auto-immune diseases. Nat Clin Pract Rheumatol. 2006;2:99-106.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
3. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349: 1436-1442.
4. Sigal LH. Basic science for the clinician 44: atherosclerosis: an immu-nologically mediated (autoimmune?) disease. J Clin Rheumatol. 2007;13: 160-168.
5. Blasi C. The autoimmune origin ofatherosclerosis. Atherosclerosis. 2008; 201:17-32.
6. Rose N, Afanasyeva M. Autoimmunity: busting the atherosclerotic plaque. Nat Med. 2003;9:641-642.
7. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci US A. 1995;92:3893-3897.
8. Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med. 2008;263:517-527.
9. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6:508-519.
10. Benagiano M, D'Elios MM, Amedei A, Azzurri A, van der Zee R, Ciervo A, Rombola G, Romagnani S, Cassone A, Del Prete G. Human 60-kDa heat shock protein is a target autoantigen of T cells derived from atherosclerotic plaques. JImmunol. 2005;174:6509-6517.
11. Businaro R, Profumo E, Tagliani A, Buttari B, Leone S, D'Amati G, Ippoliti F, Leopizzi M, D'Arcangelo D, Capoano R, Fumagalli L, Salvati B, Rigano R. Heat-shock protein 90: a novel autoantigen in human carotid atherosclerosis. Atherosclerosis. 2009;207:74-83.
12. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regu-latory pathways. Physiol Rev. 2006;86:515-581.
13. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stim-ulator of osteoclastogenesis. J Clin Invest. 1999;103:1345-1352.
14. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y. Increased expression of interleukin 17in inflammatory bowel disease. Gut. 2003;52:65-70.
15. Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S, Link H. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler. 1999;5:101-104.
16. Eid RE, Rao DA, Zhou J, Lo SF, Ranjbaran H, Gallo A, Sokol SI, Pfau S, Pober JS, Tellides G. Interleukin-17 and interferon-{gamma} are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation. 2009; 119:1424-1432.
17. Hashmi S, Zeng QT. Role ofinterleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis. 2006;17:699-706.
18. Cheng X, Yu X, Ding YJ, Fu QQ, Xie JJ, Tang TT, Yao R, Chen Y, Liao YH. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol. 2008;127:89-97.
19. Smith EB. The influence of age and atherosclerosis on the chemistry of aortic intima. 2. Collagen and mucopolysaccharides. J Atheroscler Res. 1965;5:241-248.
20. Franco C, Hou G, Ahmad PJ, Fu EY, Koh L, Vogel WF, Bendeck MP. Discoidin domain receptor 1 (ddr1) deletion decreases atherosclerosis by accelerating matrix accumulation and reducing inflammation in low-density lipoprotein receptor-deficient mice. Circ Res. 2008;102: 1202-1211.
21. Burlingham WJ, Love RB, Jankowska-Gan E, Haynes LD, Xu Q, Bobadilla JL, Meyer KC, Hayney MS, Braun RK, Greenspan DS, Gopalakrishnan B, Cai J, Brand DD, Yoshida S, Cummings OW, Wilkes DS. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest. 2007;117:3498-3506.
22. Iwata T, Philipovskiy A, Fisher AJ, Presson RG Jr, Chiyo M, Lee J, Mickler E, Smith GN, Petrache I, Brand DB, Burlingham WJ, Gopalakrishnan B, Greenspan DS, Christie JD, Wilkes DS. Anti-type V collagen humoral immunity in lung transplant primary graft dysfunction. J Immunol. 2008;181:5738-5747.
23. Bobadilla JL, Love RB, Jankowska-Gan E, Xu Q, Haynes LD, Braun RK, Hayney MS, Munoz del Rio A, Meyer K, Greenspan DS, Torrealba J, Heidler KM, Cummings OW, Iwata T, Brand D, Presson R, Burlingham WJ, Wilkes DS. TH-17, monokines, collagen type V, and primary graft dysfunction in lung transplantation. Am J Respir Crit Care Med. 2008; 177:660-668.
24. Ooshima A. Collagen alpha B chain: increased proportion in human atherosclerosis. Science. 1981;213:666-668.
25. Fichard A, Kleman JP, Ruggiero F. Another look at collagen V and XI molecules. Matrix Biol. 1995;14:515-531.
26. Haralson MA, Mitchell WM, Rhodes RK, Kresina TF, Gay R, Miller EJ. Chinese hamster lung cells synthesize and confine to the cellular domain a collagen composed solely of B chains. Proc Natl Acad Sci USA. 1980;77:5206-5210.
27. Chanut-Delalande H, Fichard A, Bernocco S, Garrone R, Hulmes DJ, Ruggiero F. Control of heterotypic fibril formation by collagen V is determined by chain stoichiometry. J Biol Chem. 2001;276:24352-24359.
28. Rodriguez DS, Jankowska-Gan E, Haynes LD, Leverson G, Munoz A, Heisey D, Sollinger HW, Burlingham WJ. Immune regulation and graft survival in kidney transplant recipients are both enhanced by human leukocyte antigen matching. Am J Transplant. 2004;4:537-543.
29. Burlingham WJ, Jankowska-Gan E, Vanbuskirk AM, Pelletier RP, Orosz C,Delayed type hypersensitivity responses. In: Lotze MT, Thomson AW, eds. Measuring Immunity: Basic Science and Clinical Practice. San Diego, Calif: Elsevier; 2005:407-418.
30. Molitor-Dart ML, Andrassy J, Kwun J, Kayaoglu HA, Roenneburg DA, Haynes LD, Torrealba JR, Bobadilla JL, Sollinger HW, Knechtle SJ, Burlingham WJ. Developmental exposure to noninherited maternal antigens induces CD4+ T regulatory cells: relevance to mechanism of heartallografttolerance. J Immunol. 2007;179:6749-6761.
31. Yoshida S, Haque A, Mizobuchi T, Iwata T, Chiyo M, Webb TJ, Baldridge LA, Heidler KM, Cummings OW, Fujisawa T, Blum JS, Brand DD, Wilkes DS. Anti-type V collagen lymphocytes that express IL-17 and IL-23 induce rejection pathology in fresh and well-healed lung transplants. Am J Transplant. 2006;6:724-735.
32. Katsuda S, Okada Y, Minamoto T, Oda Y, Matsui Y, Nakanishi I. Collagens in human atherosclerosis. Immunohistochemical analysis using collagen type-specific antibodies. Arterioscler Thromb. 1992;12: 494-502.
33. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hyper-cholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468-471.
34. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA. 1995;92:8264-8268.
35. Zhou X, Nicoletti A, Elhage R, Hansson GK. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation. 2000;102:2919-2922.
36. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340:115-126.
37. Nilsson J, Hansson GK. Autoimmunity in atherosclerosis: a protective response losing control? J Intern Med. 2008;263:464-478.
38. Sumpter TL, Wilkes DS. Role of autoimmunity in organ allograft rejection: a focus on immunity to type V collagen in the pathogenesis of lung transplant rejection. Am J Physiol Lung Cell Mol Physiol. 2004;286: L1129-L1139.
39. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994;14:133-140.
40. Nathan SD, Basavaraj A, Reichner C, Shlobin OA, Ahmad S, Kiernan J, Burton N, Barnett SD. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med. 2010;104:1035-1041.
41. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, Cianfarani F, Odorisio T, Traidl-Hoffmann C, Behrendt H, Durham SR, Schmidt-Weber CB, Cavani A. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009;119:3573-3585.
42. Mallat Z, Taleb S, Ait-Oufella H, Tedgui A. The role of adaptive T cell immunity in atherosclerosis. J Lipid Res. 2009;50(Suppl):S364-S369.
43. Wang XL, Liu SX, Wilcken DE. Circulating transforming growth factor beta 1 and coronary artery disease. Cardiovasc Res. 1997;34:404-410.
44. Dansky HM, Charlton SA, Harper MM, Smith JD. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci US A. 1997;94:4642-4646.
45. Daugherty A, Pure E, Delfel-Butteiger D, Chen S, Leferovich J, Roselaar SE, Rader DJ. The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E\/\mice. J Clin Invest. 1997;100: 1575-1580.
46. Weber C, Zernecke A, Libby P. The multifaceted contributions of leu-kocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol. 2008;8:802-815.
47. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, Zoll J, Merval R, Esposito B, Cohen JL, Fisson S, Flavell RA, Hansson GK, Klatzmann D, Tedgui A, Mallat Z. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med. 2006;12:178-180.
48. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, Soubrier F, Esposito B, Duez H, Fievet C, Staels B, Duverger N, Scherman D, Tedgui A. Protective role of interleukin-10 in atheroscle-rosis. Circ Res. 1999;85:e17-e24.
49. Mallat Z, Gojova A, Brun V, Esposito B, Fournier N, Cottrez F, Tedgui A, Groux H. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation. 2003;108:1232-1237.
50. Nilsson J, Fredrikson GN, Bjorkbacka H, Chyu KY, Shah PK. Vaccines modulating lipoprotein autoimmunity as a possible future therapy for cardiovascular disease. J Intern Med. 2009;266:221-231.
51. Yasufuku K, Heidler KM, O'Donnell PW, Smith GN Jr, Cummings OW, Foresman BH, Fujisawa T, Wilkes DS. Oral tolerance induction by type V collagen downregulates lung allograft rejection. Am J Respir Cell Mol Biol. 2001;25:26-34.
52. Yamada Y, Sekine Y, Yoshida S, Yasufuku K, Petrache I, Benson HL, Brand DD, Yoshino I, Wilkes DS. Type V collagen-induced oral tol-erance plus low-dose cyclosporine prevents rejection of MHC class I and II incompatible lung allografts. J Immunol. 2009;183:237-245.